Journal of gastrointestinal oncology最新文献

{"title":"The combination of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), interventional hepatoma therapy, targeted therapy, and immunotherapy: a case series of a novel AITI conversion therapy model.","authors":"Zhu Chen, Xingyu Chen, Haiyang Hu, Kai Chen, Heng Xiao, Chengyou Du, Xiang Lan","doi":"10.21037/jgo-2025-204","DOIUrl":"10.21037/jgo-2025-204","url":null,"abstract":"<p><strong>Background: </strong>Conversion therapy has been a hot field of hepatocellular carcinoma (HCC). The combination of interventional hepatoma therapy, targeted therapy and immunotherapy is an emerging conversion therapy, but its conversion efficiency has not been demonstrated. Its emergence limited the use of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). The way of turning unresectable tumors into resectable tumors is being explored. We integrated the ALPPS, interventional hepatoma therapy, targeted therapy, immunotherapy and proposed a novel conversion therapy named AITI.</p><p><strong>Case description: </strong>Patients treated with the AITI conversion therapy model in The First Affiliated Hospital of Chongqing Medical University were retrospectively analyzed. ALPPS was selected for patients who, after physician evaluation, were considered potentially resectable but had insufficient future liver remnant (FLR). Interventional hepatoma therapy, targeted therapy, and immunotherapy were used before first-stage ALPPS or between stages. Five patients received AITI conversion therapy model. Three patients underwent traditional conversion therapy between the two stages of the ALPPS and achieved satisfactory hypertrophy, while two patients achieved radical resection through ALPPS following conversion therapy. Among all patients, the mean residual volume before the first-stage surgery was 580±245 mL, and increased to 701±295 mL before the second-stage surgery. The mean duration of the first-stage surgery was 175.00±17.32 minutes with a blood loss of 210.00±124.50 mL. For the second-stage surgery, the mean duration was 234.00±25.35 minutes with a blood loss of 400.00±70.71 mL. The average duration of treatment was 136.8±98.3 days.</p><p><strong>Conclusions: </strong>The AITI conversion therapy model is safe and affective. This approach can provide more opportunities for unresectable patients to achieve radical resection.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1736-1748"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Asiaticoside inhibits epithelial-mesenchymal transition and stem cell-like properties of pancreatic cancer PANC-1 cells by blocking the activation of p65 and p38MAPK.","authors":"","doi":"10.21037/jgo-2025b-03","DOIUrl":"10.21037/jgo-2025b-03","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/jgo-20-533.].</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1791-1795"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New dosing schedules in pre-treated patients with metastatic colorectal cancer.","authors":"Per Pfeiffer, Line Schmidt Tarpgaard","doi":"10.21037/jgo-2025-492","DOIUrl":"10.21037/jgo-2025-492","url":null,"abstract":"","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1773-1778"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report of carcinoid syndrome with multi-organ involvement.","authors":"Matthew Everett, Saurin Chokshi","doi":"10.21037/jgo-2025-26","DOIUrl":"10.21037/jgo-2025-26","url":null,"abstract":"<p><strong>Background: </strong>Carcinoid syndrome (CS) is a rare complication of neuroendocrine tumors (NETs). Characterized by cutaneous flushing, diarrhea, abdominal pain, and long-term risk for valvular heart disease, these components occur in a fraction of patients with advanced disease. Early recognition through history taking, physical and laboratory examination, and clinical imaging is paramount to successful management.</p><p><strong>Case description: </strong>We report a case of CS in a 21-year-old male patient found to have a metastatic gastrointestinal, well differentiated (Ki67 <3%) NET. The patient presented with cutaneous flushing, diarrhea, abdominal pain, dyspnea, ascites, and peripheral edema. On imaging, he was found to have a massive left pleural effusion, innumerable enhancing hepatic lesions, mesenteric lymphadenopathy, and large-volume ascites. Cardiac imaging further showed severe tricuspid regurgitation and right heart failure. Biopsy of the enhancing hepatic lesions showed a grade 1 NET of gastrointestinal origin. Urine testing revealed markedly high serotonin metabolites. The patient was started on somatostatin analogues, which resulted in improved control of diarrhea and flushing. Thoracoscopic surgery improved pleural effusion accumulation, and recurrent abdominal ascites was treated with paracentesis when necessary. He was also referred to cardiothoracic surgery tricuspid valve replacement surgery.</p><p><strong>Conclusions: </strong>Our case illustrates the classic characteristics of CS as well as valvular heart disease supported by clinical imaging of the syndrome's involvement of multiple organ systems. These findings are important for physicians to recognize as early recognition of CS can lower the risk of long-term complications of carcinoid heart disease. Additionally, patients with limited access to healthcare may be at risk of later CS presentation.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1756-1762"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor necrosis, an independent prognostic factor for predicting gastric gastrointestinal stromal tumors.","authors":"Kunlong Chang, Renjie Li, Peng Zhang, Tao Chen, Haibo Qiu, Yongjian Zhou, Chunyan Du, Xiaonan Yin, Fang Pan, Guoliang Zheng, Yan Zhao, Xiufeng Liu, Jian Li, Bo Zhang, Ye Zhou, Jiang Yu, Kaixiong Tao, Yong Li, Xingyu Feng","doi":"10.21037/jgo-2025-89","DOIUrl":"10.21037/jgo-2025-89","url":null,"abstract":"<p><strong>Background: </strong>Tumor necrosis has been identified as an independent adverse prognostic factor in various human malignancies; however, its prognostic value in gastric gastrointestinal stromal tumors (gGISTs) remains uncertain. This study aimed to investigate the association between tumor necrosis and overall survival (OS) in patients with gGIST who underwent radical surgical resection.</p><p><strong>Methods: </strong>In this retrospective cohort study, clinical and pathological data from 1,463 patients with gGIST were analyzed. The association between tumor necrosis and OS was assessed using univariate analysis with log-rank tests and multivariate analysis with Cox proportional hazards regression models.</p><p><strong>Results: </strong>Tumor necrosis was observed in 238 patients (16.3%) and was significantly associated with tumor location (P=0.044), tumor size (P<0.001), mitotic count (P<0.001), and modified National Institutes of Health (NIH) risk categories (P<0.001). Multivariate analysis confirmed tumor necrosis as an independent unfavorable predictor of OS (P=0.02). Incorporating tumor necrosis into the modified NIH risk classification enabled the stratification of patients into five prognostically distinct groups (P<0.001).</p><p><strong>Conclusions: </strong>Tumor necrosis was identified as an independent adverse prognostic factor in gGIST, and its integration into the modified NIH classification improves prognostic accuracy, supporting a refined risk stratification system for enhanced clinical decision-making and patient management.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1393-1402"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of anlotinib combined with camrelizumab and chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma on tumor immune microenvironment.","authors":"Mingfang Xu, Yingda Liu, Xunjie Kuang, Xiuyong Liao, Xiaodong Zhao","doi":"10.21037/jgo-2025-30","DOIUrl":"10.21037/jgo-2025-30","url":null,"abstract":"<p><strong>Background: </strong>Esophageal squamous cell carcinoma (ESCC) presents significant therapeutic challenges due to limited treatment options. While immune checkpoint inhibitors (ICIs) combined with chemotherapy have demonstrated efficacy, variable response rates underscore the necessity for enhanced therapeutic approaches. Anlotinib, a multi-target tyrosine kinase inhibitor, has shown synergistic effects with ICIs in clinical practice. However, its influence on the tumor immune microenvironment (TIME) in ESCC requires further elucidation. This study aimed to investigate anlotinib's effects on the TIME.</p><p><strong>Methods: </strong>In our phase II trial (NCT04471480), we analyzed 8 advanced ESCC patients who achieved operability following treatment with anlotinib, camrelizumab, and chemotherapy (TCAC group). A control group (TCC group) comprised 8 patients from a separate neoadjuvant trial who received identical treatment, excluding anlotinib. Tumor-infiltrating immune cell populations (CD4⁺, CD8⁺, CD20⁺, CD68⁺, FOXP3⁺) were evaluated using multiplex immunofluorescence. Additional mechanistic insights were obtained through RNA sequencing (RNA-seq) and enzyme-linked immunosorbent assay (ELISA).</p><p><strong>Results: </strong>Baseline immune cell profiles showed no significant intergroup differences. Post-treatment analysis revealed the TCAC group had significantly elevated CD8⁺ cell proportions and reduced FOXP3⁺ cell proportions compared to controls (P<0.05). Within the TCAC cohort, pretreatment immune cell distributions were comparable between pathological complete response (pCR) and non-pCR patients. However, post-treatment pCR patients demonstrated significantly higher CD8⁺ and lower FOXP3⁺ cell levels versus non-pCR cases (P<0.05). RNA-seq and ELISA analyses suggested anlotinib's potential to enhance the immune microenvironment through C-C motif chemokine ligand 5 (CCL5) upregulation.</p><p><strong>Conclusions: </strong>The combination of anlotinib with camrelizumab and chemotherapy appears to modify the ESCC immune microenvironment by promoting cytotoxic CD8⁺ T cell infiltration while suppressing FOXP3⁺ regulatory T cells, possibly mediated through CCL5 induction. These results warrant further investigation of anlotinib's immunomodulatory potential in ESCC combination therapies.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1366-1379"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in precision therapies for advanced cholangiocarcinoma: inhibitors of FGFR1-3.","authors":"Jonathan Wadsley","doi":"10.21037/jgo-2025-274","DOIUrl":"10.21037/jgo-2025-274","url":null,"abstract":"","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1779-1781"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of the systemic immune inflammation index in predicting the efficacy of neoadjuvant chemotherapy in patients with gastric cancer: a multicenter retrospective clinical study.","authors":"Li Yang, Min Chen, Wei Wang, Minghui Meng, Fengying Wu, Jiani Lv, Arvind Sahu, Yuanyuan Jiao","doi":"10.21037/jgo-2025-423","DOIUrl":"10.21037/jgo-2025-423","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemotherapy is the primary treatment for locally advanced gastric cancer, and the efficacy of neoadjuvant chemotherapy has an important impact on the long-term prognosis of patients with gastric cancer. Accurately predicting the efficacy of neoadjuvant chemotherapy in patients with gastric cancer is critical to treatment planning, so it is necessary to identify the biological indicators of treatment efficacy. This study aimed to analyze the value of the systemic immune inflammation index in predicting the efficacy of neoadjuvant chemotherapy in patients with gastric cancer.</p><p><strong>Methods: </strong>From January 2020 to December 2021, a total of 182 patients with locally advanced gastric cancer admitted to The Fifth Hospital of Shijiazhuang Hebei Province and Yangxin County People's Hospital and who received neoadjuvant chemotherapy were retrospectively enrolled. The patients were divided into an objective remission group (n=112) and a control group (no objective remission; n=70) according to the efficacy of neoadjuvant chemotherapy. Multivariate logistics regression was used to analyze the influencing factors of efficacy in patients with gastric cancer treated with neoadjuvant chemotherapy. Finally, the patients of the two groups were followed up for 3 years, and the recurrence, metastasis, and mortality of the two groups were observed.</p><p><strong>Results: </strong>There were significant differences in the systemic immune inflammatory index, Ki-67 expression, lymph node metastasis, and tumor cell differentiation between the two groups (P<0.05). A high systemic immune inflammatory index score and poorly differentiated cancer were unfavorable factors for objective remission in patients treated with neoadjuvant chemotherapy, with relative risks of 0.974 (95% confidence interval: 0.965-0.982) and 0.086 (95% confidence interval: 0.022-0.338), respectively. Meanwhile, a high Ki-67 expression was a favorable factor for objective remission in patients with gastric cancer treated with neoadjuvant chemotherapy, with a relative risk of 1.090 (95% confidence interval: 1.034-1.148). The systemic immune inflammation index demonstrated high value in predicting objective remission in patients with gastric cancer treated with neoadjuvant chemotherapy, with an area under the curve of 0.947 (95% confidence interval: 0.914-0.981). Compared with that in the control group, the radical resection rate in the objective remission group was significantly higher (P>0.05). The 3-year recurrence rate, metastasis rate, and mortality rate were significantly lower in the objective remission group than in the control group (P<0.05).</p><p><strong>Conclusions: </strong>The efficacy of neoadjuvant chemotherapy in patients with locally advanced gastric cancer has an important impact on prognosis, and the systemic immune inflammation index is a reliable biological indicator for the efficacy of this treatment.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1434-1442"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence and risk factors of venous thromboembolism in patients with pancreatic cancer: a systematic review and meta-analysis.","authors":"Xinyao Zhou, Yunlan Jiang, Heyao Xu, Xiaodi Bai, Siyu Lin, Ting Xu, Shulan Liu","doi":"10.21037/jgo-2025-132","DOIUrl":"10.21037/jgo-2025-132","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) is a common complication of malignant tumors. The incidence of VTE in patients with pancreatic cancer (PC) may be higher than that in other patients, but varies significantly between studies. Therefore, we aimed to investigate the incidence and risk factors for VTE in patients with PC.</p><p><strong>Methods: </strong>We searched relevant studies from seven electronic databases from their inception to December 25, 2024. The incidence of VTE, odds ratio (OR), and 95% confidence interval (CI) were extracted to evaluate the incidence of VTE and its risk factors in PC patients. The robustness of the results was tested by sensitivity analysis. We used funnel plot and Egger test to assess publication bias.</p><p><strong>Results: </strong>A total of 61 articles were included in this study, including 29,921 patients. The incidence of VTE was 15.6%. Tumor location (OR =1.92; 95% CI: 1.25-2.94), poorly differentiated (OR =2.54; 95% CI: 1.53-4.23), tumor, node, metastasis (TNM) stage IV (OR =2.82; 95% CI: 1.12-7.08), metastasis (OR =2.16; 95% CI: 1.59-2.93) and higher D-dimer (OR =4.33; 95% CI: 1.26-14.86) were risk factors for VTE.</p><p><strong>Conclusions: </strong>The incidence of VTE is high in patients with PC. The tumor located in the body or tail, poorly differentiated, stage IV cancer, distant metastasis, and increased D-dimer levels after surgery are risk factors for VTE. The limitations mainly include high heterogeneity. This indicates that such high-risk patients should be identified early in clinical work, and attention should be paid to the evaluation and intervention for VTE in patients with PC.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1667-1681"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical value of spectral computed tomography reconstruction technology for the anatomy of the superior mesenteric artery in laparoscopic radical right hemicolectomy for colon cancer: a cross-sectional study.","authors":"Jinghao Chen, Hao Tian, Ke Yu, Shumin Tao, Bin Bai, Anyi Song, Hongmei Gu","doi":"10.21037/jgo-2025-167","DOIUrl":"10.21037/jgo-2025-167","url":null,"abstract":"<p><strong>Background: </strong>The superior mesenteric artery (SMA) has numerous branches and a high rate of anatomical variation, making it challenging to manage during surgery. This study aimed to evaluate the clinical utility of dual energy computed tomography (CT) three-dimensional (3D) reconstruction combined with arteriovenous image fusion technology for assessing SMA variations. The goal is to aid in surgical planning for laparoscopic radical resection of right colon cancer, using the SMA as the primary surgical approach.</p><p><strong>Methods: </strong>We performed a retrospective analysis of clinical and imaging data from patients with right colon cancer who underwent enhanced spectral CT of the abdomen and pelvis before surgery at Nantong University Affiliated Hospital from January 2020 to June 2024. Using post-processing techniques to reconstruct SMA images, the study evaluated the SMA root position, measured the distance between the roots of the right branches of the SMA, analyzed their relationship with patient gender and body mass index (BMI), and summarized the types of right branches of the SMA. Additionally, the relationship between the middle colic artery (MCA), right colic artery (RCA), ileocolic artery (ICA), and the superior mesenteric vein (SMV) positions were analyzed in relation to patient clinical characteristics.</p><p><strong>Results: </strong>The SMA root was mostly located at the L1 vertebral level (74.68%, 236/316), with a vertebral range between T12-L2. The distance from the SMA root to the abdominal aorta (D_SMA-AB) was 115.97±11.82 mm, and this distance increased with higher BMI in males. Type I SMA (presence of RCA) accounted for 39.87% (126/316), Type II (absence of RCA) accounted for 60.13% (190/316), with the distance between the root of the MCA and the ICA (d_MCA-ICA) being longer in type II. 91.27% (115/126) of the RCA was anterior to the SMV. When the RCA was posterior, the ICA was always posterior to the SMV. The ICA was anterior to the SMV in about 50.63% (160/316) of cases, with a higher incidence in males and those with a shorter d_MCA-ICA.</p><p><strong>Conclusions: </strong>Spectral CT 3D reconstruction and arteriovenous image fusion technology can accurately assess the anatomical features of the SMA and the relationship between the right branch vessels and the SMV, helping to develop reasonable surgical plans for laparoscopic radical right hemicolectomy in patients with right colon cancer using an \"SMA-prioritized approach\".</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 4","pages":"1461-1473"},"PeriodicalIF":2.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}